Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

KCNH2 Polymorphisms on the QTc Interval in Kelantanese Malays Patients Receiving Methadone Maintenance Therapy (MMT)

torstai 26. heinäkuuta 2018 päivittänyt: Muhammad Irfan Abdul Jalal, Universiti Sains Malaysia

Influence of KCNH2 Polymorphisms on the QTc Interval in Kelantanese Malays Patients Receiving Methadone Maintenance Therapy (MMT) in Malaysia

Methadone maintenance therapy (MMT) is one of the modalities to prevent HIV transmission among injected drug users, particularly in opioid-dependent users. However, methadone-associated cardiotoxicity is one of the fatal adverse events that limit the widespread usage in certain groups of opioid-dependent patients. This is a cross-sectional study aimed to investigate the association between 4 KCNH2 SNPs (1539C>T, in exon 6 of KCNH2 gene; 1956T>C, in exon 8 of KCNH2 gene), 2350C>T (in exon 9 of KCNH2 gene), 2690A>C (Exon 11 of KCNH2 gene)) and prolongation of QTc interval in opioid-dependent Kelantanese Malays who are the recipients of Methadone Maintenance Therapy. The investigators hypothesized that subjects with minor alleles of those 4 SNPs will have longer QTc intervals than those with major alleles, adjusting for the effects of other confounding factors such as age and gender of the subjects, plasma methadone trough levels, hypokalemia, hypocalcemia and hypomagnesemia. The investigators also aimed to provide a model that will reliably predict the magnitude QTc based on the SNPs data and other covariates mentioned above. This will greatly assist in identifying methadone recipients who are at risk of developing prolonged QTc or the more fatal torsade de pointes.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Introduction

Methadone maintenance therapy (MMT) is one of the modalities to prevent HIV transmission among injected drug users, particularly in opioid-dependent users. However, methadone-associated cardiotoxicity is one of the fatal adverse events that limit the widespread usage in certain groups of opioid-dependent patients.

Study hypotheses / aims

The investigators hypothesized that subjects with minor alleles of those 4 SNPs would have longer QTc intervals than those with major alleles, adjusting for the effects of other confounding factors such as age and gender of the subjects, plasma methadone trough levels, hypokalemia, hypocalcemia and hypomagnesemia. The investigators also aimed to provide a model that will reliably predict the magnitude QTc based on the SNPs data and other covariates mentioned above. This will greatly assist in identifying methadone recipients who are at risk of developing prolonged QTc or the more fatal torsade de pointes.

Study Design and Sample Size Calculation

This is a cross-sectional study aimed to investigate the association between 4 KCNH2 SNPs (1539C>T, in exon 6 of KCNH2 gene; 1956T>C, in exon 8 of KCNH2 gene), 2350C>T (in exon 9 of KCNH2 gene), 2690A>C (Exon 11 of KCNH2 gene)) and prolongation of QTc interval in opioid-dependent Kelantanese Malays who are the recipients of Methadone Maintenance Therapy . The sample size was calculated using single-proportion formula and the information required was based on a similar prior study conducted among Singaporean Malay. It was concluded that the sample size required is 105 patients. Since eligible patients were lacking, the convenience (non-probability) sampling method was used.

During the initial visit, relevant clinico-demographic details such as age, gender, history of drug addiction and psychiatric illnesses, drug dependency patterns, other drug usage and treatment-related issues for each patient were gathered. Subsequently a validated Malay version of Subjective Opioid Withdrawal Scale (SOWS) questionnaire was administered to assess any opioid withdrawal symptoms experienced by study participants.

Five (5) mls of blood was then withdrawn for each subject for the ascertainment of relevant biochemical profile (serum potassium, magnesium, calcium), plasma methadone trough levels, and KCNH2 SNPs genotyping. Drug screening for substances such as MDMA, benzodiazepines methamphetamine, cannabis, marijuana were also carried out using urine dipstick test at urine collection point. The colour and temperature of the urine were also recorded.

QT measurement was obtained using calibrated Welch Allyn CP 50™ ECG (Electrocardiograph) (Welch Allyn Australia Pty Ltd., New South Wales, Australia) machine, printed at a paper speed of 25mm/s and voltage of 10mm/mV. QTc measurement was then manually calculated using Fredericia's formula to correct for heart rate (R-R interval). All trained personnel who were responsible for obtaining QTc measurement from each patient were blinded to other information on serum biochemical profiles and methadone trough levels.

KCNH2 Genotyping

The DNA was extracted according to procedures modified from Bethesda Research Laboratories based on the revisions made to the Brinboam and Doly method. The quantity and quality of the extracted DNA were determined using NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Inc. Wilmington, USA) with measurements done at 260 and 280 nm. The integrity of the extracted DNA was determined using 2% agarose gel electrophoresis performed at 70 Volts for 90 minutes.

The DNA in all samples were amplified for all 4KCNH2 SNPs were performed using 2-step nested allele-specific multiplex polymerase chain reaction (PCR). The primers (both forward and reverse) were designed according to the published sequence for KCNH2 (NC_000007.13). To improve primer specificity, mismatch at its 3´ ends that were specific to either the variant sequence or wild-type DNA sequence at the specified locus was made to the primers. Besides, the primers were also designed and manipulated to differentiate between the different single nucleotide changes/alleles during PCR amplification. To verify primers specificity, the BLAST program at NCBI (http://www.ncbi.nlm.nih.gov/ blast) was used.

In the first multiplex PCR, exon 6,8,9 and 11 were amplified under the following condition: pre-denaturation at 95°C for 1 minute followed by 25-cycle of denaturation at 95°C for 15 seconds, annealing for 65°C for 15 seconds, and extension at 72°C for 10 seconds. Upon full 25-cycle completion, final extension phase lasted for 72°C for 7 minutes. The PCR products (amplicons) were then resolved using 2% agarose gel electrophoresis at 130 Volts for 90 minutes.

The PCR products of the first multiplex PCR were then used as templates for second PCR which targeted the 4 respective SNPs region for amplification. This was performed under the following condition:pre-denaturation at 95°C for 1 minute followed by 25-cycle of denaturation at 95°C for 15 seconds, annealing for 69°C for 30 seconds, and extension at 72°C for 4 seconds. Upon full 25-cycle completion, final extension phase lasted for 72°C for 7 minutes. The PCR products (amplicons) were then resolved using 2% agarose gel electrophoresis at 130 Volts for 90 minutes.

The first products of the amplified regions in the Exons 6, 8, 9, and Exon11 were subsequently submitted for direct DNA sequencing. QIAquick PCR purification kit (Qiagen, USA) was used for purification of the PCR products. DNA sequencing was carried out by applying 3130XL genetic analyzer DNA sequencer (ABI, USA). The results were compared with the published sequences for KCNH2 in the NCBI, accession number (NC_000007.13)

Statistical Analysis

The select equally likely or more extreme samples (SELOME) version of the Fisher's exact test was employed to examine whether the distribution of the SNP alleles and genotype follow the Hardy-Weinberg Equilibrium (HWE) assumption. Those SNPs that significantly deviated from the HWE assumption were dropped from further analysis.

To examine the associations between the 4SNPs and QTc interval (measured as continuous variable) and build a statistical model that can reliably predict QTc intervals, simple and multiple linear regression methods were used. Age and gender of the patients, plasma methadone trough levels, serum potassium, calcium and magnesium were treated as confounding factors whose effects on QTc were adjusted for.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Todellinen)

111

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Kelantan
      • Kubang Kerian, Kelantan, Malesia, 15350
        • Hospital Universiti Sains Malaysia

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Kelantanese Malay opioid-dependent subjects who were on Methadone Maintenance Therapy (MMT) in the Eastern-coastal state of Kelantan, Malaysia.

Kuvaus

Inclusion Criteria:

  • Opioid-dependent subjects aged 18 years and above
  • Opioid-dependent subjects who were on Methadone Maintenance Therapy (MMT) for 6 months or longer and had stable plasma methadone concentration
  • Malay ancestry up to 3 generations
  • A history of good compliance with Directly-Observed Therapy (DOT)

Exclusion Criteria:

  • Opioid-dependent subjects who were aggressive and had active psychiatric illnesses
  • Opioid-dependent subjects with chronic medical and surgical illnesses
  • Opioid-dependent subjects with cardiac structural defects
  • Inability to communicate in Malay or English

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
QTc Interval
Aikaikkuna: First screening visit
QT interval (measured in milliseconds) obtained from ECG reading that is then divided by the shortest R-R interval to the power of 0.33 (Fredericia's formula).
First screening visit

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Muslih AbdulKarim Ibrahim, PhD, Hawler University

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Hyödyllisiä linkkejä

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 1. helmikuuta 2011

Ensisijainen valmistuminen (Todellinen)

Maanantai 31. joulukuuta 2012

Opintojen valmistuminen (Todellinen)

Maanantai 31. joulukuuta 2012

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 18. heinäkuuta 2018

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 19. heinäkuuta 2018

Ensimmäinen Lähetetty (Todellinen)

Perjantai 27. heinäkuuta 2018

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 30. heinäkuuta 2018

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 26. heinäkuuta 2018

Viimeksi vahvistettu

Sunnuntai 1. heinäkuuta 2018

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa